» Articles » PMID: 33332430

Serum Krebs Von Den Lungen-6 Level Predicts Disease Progression in Interstitial Lung Disease

Overview
Journal PLoS One
Date 2020 Dec 17
PMID 33332430
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Disease progression (DP) in interstitial lung disease (ILD) is variable and difficult to predict. In previous reports, serum Krebs von den Lungen-6 (KL-6) was suggested to be useful in diagnosing and predicting survival in ILD. The aim of our study was to investigate the usefulness of serum KL-6 as a predictor of DP in ILD. Clinical data of 199 patients with ILD (idiopathic pulmonary fibrosis: 22.8%) were prospectively collected and serum KL-6 levels were measured. DP was defined as a relative decline in forced vital capacity (FVC) ≥ 10%, acute exacerbation, or death during follow-up. The median follow-up period was 11.1 months. The mean age of the subjects was 62.2 years, and 59.8% were male. DP occurred in 21.6% of patients. The progressed group showed lower FVC, lower diffusing capacity for carbon monoxide, lower the minimum oxygen saturation during the 6-minute walk test, higher fibrosis scores on high-resolution computed tomography, and higher KL-6 levels (826.3 vs. 629.0 U/mL; p < 0.001) than those of the non-progressed group. In receiver operating characteristic curve analysis, serum KL-6 levels were a significant predictor of DP in ILD (area under the curve = 0.629, p = 0.009, and the optimal cut-off level was 811 U/mL). In multivariable Cox analysis, high serum KL-6 levels (≥ 800 U/mL) were only independently associated with DP in ILD (HR 2.689, 95% CI 1.445-5.004, P = 0.002). Serum KL-6 levels might be useful to predict DP in patients with ILD.

Citing Articles

Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.

Shin B, Oh Y, Kim J, Park S, Lee K, Lee H BMC Pulm Med. 2024; 24(1):523.

PMID: 39427156 PMC: 11490112. DOI: 10.1186/s12890-024-03344-8.


Clinical Utility of Bronchoalveolar Lavage Neutrophilia and Biomarkers for Evaluating Severity of Chronic Fibrosing Interstitial Lung Diseases.

Shadrach B, Dutt N, Elhence P, Banerjee M, Chauhan N, Jalandra R Cureus. 2023; 15(7):e42162.

PMID: 37602059 PMC: 10439013. DOI: 10.7759/cureus.42162.


[Interstitial Lung Disease].

Margallo Iribarnegaray J, Churruca Arrospide M, Matesanz Lopez C, Perez Rojo R Open Respir Arch. 2023; 5(2):100248.

PMID: 37496878 PMC: 10369608. DOI: 10.1016/j.opresp.2023.100248.


Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.

Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q Pulm Ther. 2023; 9(3):295-307.

PMID: 37209374 PMC: 10199290. DOI: 10.1007/s41030-023-00226-y.


Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease.

Fu H, Zheng Z, Zhang Z, Yang Y, Cui J, Wang Z Clin Rheumatol. 2023; 42(7):1917-1929.

PMID: 36929316 PMC: 10266998. DOI: 10.1007/s10067-023-06570-3.


References
1.
Wanger J, Clausen J, Coates A, Pedersen O, Brusasco V, Burgos F . Standardisation of the measurement of lung volumes. Eur Respir J. 2005; 26(3):511-22. DOI: 10.1183/09031936.05.00035005. View

2.
Vesely R, Vargova V, Ravelli A, Massa M, Oleksak E, DAlterio R . Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J Rheumatol. 2004; 31(4):795-800. View

3.
Cottin V, Nunes H, Brillet P, Delaval P, Devouassoux G, Tillie-Leblond I . Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26(4):586-93. DOI: 10.1183/09031936.05.00021005. View

4.
Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

5.
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K . Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002; 165(3):378-81. DOI: 10.1164/ajrccm.165.3.2107134. View